Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells

Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells

The PAX3-FOXO1 fusion gene functions as a transactivator and increases expression of many cancer-related genes. These lead to metastases and other unfavorable outcomes for alveolar rhabdomyosarcoma (ARMS) patients. In order to target ARMS with the PAX3-FOXO1 transactivator, we developed an Oncolytic...

Full description

Bibliographic Details
Main Authors: Hideki Yoshida, Mizuho Sato-Dahlman, Praveensingh Hajeri, Kari Jacobsen, Lisa Koodie, Chikako Yanagiba, Ryan Shanley, Masato Yamamoto
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Translational Oncology
Subjects:
Child cancer
Fusion-gene
MEF2
Soft-tissue sarcoma
Virotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304897

Similar Items

Similar Items